ANI PHARMACEUTICALS ($ANIP) posted quarterly earnings results for Q4 2025 on Friday, February 27th. The company reported earnings of $2.33 per share, beating estimates of $2.04 by $0.29. The company also reported revenue of $247,060,000, beating estimates of $236,164,241 by $10,895,759.
You can see Quiver Quantitative's $ANIP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ANI PHARMACEUTICALS Insider Trading Activity
ANI PHARMACEUTICALS insiders have traded $ANIP stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:
- CHAD GASSERT (SVP - CORP. DEV. & STRATEGY) has made 0 purchases and 2 sales selling 14,736 shares for an estimated $1,312,434.
- CHRISTOPHER MUTZ (HEAD OF RARE DISEASE) has made 0 purchases and 2 sales selling 12,355 shares for an estimated $953,600.
- PATRICK D WALSH sold 8,643 shares for an estimated $750,903
- ANTONIO R PERA sold 7,292 shares for an estimated $692,302
- KRISTA DAVIS (SVP, CHIEF HR OFFICER) has made 0 purchases and 4 sales selling 6,436 shares for an estimated $528,188.
- MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has made 0 purchases and 6 sales selling 2,600 shares for an estimated $223,805.
- RENEE P TANNENBAUM sold 1,800 shares for an estimated $146,070
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ANI PHARMACEUTICALS Hedge Fund Activity
We have seen 158 institutional investors add shares of ANI PHARMACEUTICALS stock to their portfolio, and 124 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 559,670 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $44,180,349
- MILLENNIUM MANAGEMENT LLC added 474,420 shares (+727.1%) to their portfolio in Q4 2025, for an estimated $37,450,714
- UBS GROUP AG removed 439,095 shares (-74.4%) from their portfolio in Q4 2025, for an estimated $34,662,159
- RUBRIC CAPITAL MANAGEMENT LP removed 343,414 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $27,109,101
- MACQUARIE GROUP LTD removed 291,129 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,981,723
- POINT72 ASSET MANAGEMENT, L.P. removed 277,881 shares (-69.6%) from their portfolio in Q4 2025, for an estimated $21,935,926
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 234,219 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,489,247
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ANI PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ANIP in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/10/2025
- JP Morgan issued a "Overweight" rating on 09/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/17/2025
To track analyst ratings and price targets for ANI PHARMACEUTICALS, check out Quiver Quantitative's $ANIP forecast page.
ANI PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ANIP recently. We have seen 5 analysts offer price targets for $ANIP in the last 6 months, with a median target of $115.0.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $124.0 on 01/16/2026
- Glen Santangelo from Barclays set a target price of $100.0 on 12/09/2025
- Gregory Fraser from Truist Securities set a target price of $90.0 on 10/09/2025
- Ekaterina Knyazkova from JP Morgan set a target price of $115.0 on 09/24/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $121.0 on 09/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
